ACADIA Pharmaceuticals Stock Discussion

$ACADIA Pharmaceuticals (ACAD.US)$
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
Acadia Pharmaceuticals (NASDAQ: ACAD) announced the publication of clinical data from the open-label DAFFODIL™ study in the journal Med, evaluating DAYBUE® (trofinetide) in Rett syndrome patients. The Phase 2/3 study focused on children aged 2-4 years (n=15) and demonstrated safety profiles consistent with previou...

$ACADIA Pharmaceuticals (ACAD.US)$ Acadia Pharmaceuticals Announces DAYBUE Study Results In Med Journal; Open-Label DAFFODIL Study Shows Comparable Safety For Rett Syndrome in 2-4 Age Group; Results Support FDA Approval for Ages 2+
Benzinga· 5 mins ago
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the journal Medpublished results from the open-label study, DAFFODIL, evaluating the safety, tolerability and exploratory efficacy of DAYBUE (trofinetide) in girls ages two to fou...

$ACADIA Pharmaceuticals (ACAD.US)$
Can Acadia's Rett Syndrome Treatment Change Patient Lives? New Clinical Data Reveals Key Insights

$ACADIA Pharmaceuticals (ACAD.US)$
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
6 minutes ago, 6:00 AM PST
Via BusinessWire
ACAD
Share
-- Filing marks company's first Marketing Authorization Application in Europe
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tr...

$ACADIA Pharmaceuticals (ACAD.US)$ Reuters· 1 min ago
ACADIA Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

$HWH International (HWH.US)$  13D 88.9%. China stock. Low float. SI 214%✅
$Infobird Software (IFBD.US)$  Completed $40M acquisition. China stock. Low float. 0 shares LTB✅
$Ocean Power Technologies (OPTT.US)$ Form 4 insider buying. 0 shares LTB✅
$T Stamp (IDAI.US)$ Ran today. Up after hours. Possible catalyst. Low float. 0 shares LTB✅
$Syra Health (SYRA.US)$ Recent Form 4s multiple insider loading. Low fl...

$ACADIA Pharmaceuticals (ACAD.US)$
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
Acadia Pharmaceuticals (NASDAQ: ACAD) has secured an exclusive worldwide license agreement with Saniona for SAN711, a first-in-class GABAA-α3 positive allosteric modulator.
The company plans to develop SAN711 for essential tremor treatment, with Phase 2 studies expected to begin in 2026. Under the agreement, Saniona will receive a $28 million upfront payment plus potential ...

$ACADIA Pharmaceuticals (ACAD.US)$ Reuters· 1 min ago
ACADIA Pharmaceuticals Inc - Saniona to Receive $28 Million Upfront Plus up to $582 Million in Milestones with exclusive licensing agreement with Saniona for San711

$ACADIA Pharmaceuticals (ACAD.US)$ Reuters· just
ACADIA Pharmaceuticals Enters Into an Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million